Amgen ( AMGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.9%. By the end of trading, Amgen rose $3.73 (3.8%) to $102.06 on average volume. Throughout the day, 4,129,559 shares of Amgen exchanged hands as compared to its average daily volume of 3,731,100 shares. The stock ranged in a price between $98.02-$102.33 after having opened the day at $98.16 as compared to the previous trading day's close of $98.33. Other companies within the Drugs industry that increased today were: Inovio Pharmaceuticals ( INO), up 24.6%, China Pharma ( CPHI), up 14.9%, Pharmacyclics Incorporated ( PCYC), up 12.0% and Prosensa ( RNA), up 10.5%.
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $73.6 billion and is part of the health care sector. Shares are up 14.1% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold. TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.